Brief: Pepgen Presents Preclinical Data Supporting Co's Enhanced Delivery Oligonucleotide Platform And Pgn-Edodm1 Program
06/09/2023 16:18
Sept 6 (Reuters) - PepGen Inc PEPG.O :
* PEPGEN INC. PRESENTS PGN-EDODM1 PRECLINICAL DATA
SUPPORTING THE
COMPANY’S ENHANCED DELIVERY OLIGONUCLEOTIDE PLATFORM AND
PGN-EDODM1 PROGRAM AT TWO MEDICAL CONFERENCES
Source text for Eikon: ID:nGNX4xFn4F
Further company coverage: PEPG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PepGen
See all newsDyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview